In the past week, CMPX stock has gone down by -3.35%, with a monthly decline of -30.67% and a quarterly surge of 46.07%. The volatility ratio for the week is 8.40%, and the volatility levels for the last 30 days are 9.35% for Compass Therapeutics Inc The simple moving average for the past 20 days is -8.56% for CMPX’s stock, with a 48.61% simple moving average for the past 200 days.
Is It Worth Investing in Compass Therapeutics Inc (NASDAQ: CMPX) Right Now?
The 36-month beta value for CMPX is at 1.06. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CMPX is 80.70M, and currently, shorts hold a 4.58% of that float. The average trading volume for CMPX on March 14, 2025 was 1.47M shares.
CMPX) stock’s latest price update
The stock price of Compass Therapeutics Inc (NASDAQ: CMPX) has surged by 5.26 when compared to previous closing price of 2.47, but the company has seen a -3.35% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-27 that Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 – a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the first quarter 2025. Supported initiation of an Investigator Sponsored Study (IST) evaluating tovecimig in patients with BTC in the first-line setting, with patient dosing expected in the first quarter 2025.
Analysts’ Opinion of CMPX
Many brokerage firms have already submitted their reports for CMPX stocks, with Guggenheim repeating the rating for CMPX by listing it as a “Buy.” The predicted price for CMPX in the upcoming period, according to Guggenheim is $12 based on the research report published on February 24, 2025 of the current year 2025.
Piper Sandler, on the other hand, stated in their research note that they expect to see CMPX reach a price target of $12. The rating they have provided for CMPX stocks is “Overweight” according to the report published on February 19th, 2025.
D. Boral Capital gave a rating of “Buy” to CMPX, setting the target price at $32 in the report published on December 23rd of the previous year.
CMPX Trading at -5.18% from the 50-Day Moving Average
After a stumble in the market that brought CMPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.27% of loss for the given period.
Volatility was left at 9.35%, however, over the last 30 days, the volatility rate increased by 8.40%, as shares sank -25.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +74.66% upper at present.
During the last 5 trading sessions, CMPX fell by -3.90%, which changed the moving average for the period of 200-days by +75.85% in comparison to the 20-day moving average, which settled at $2.84. In addition, Compass Therapeutics Inc saw 79.31% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CMPX
Current profitability levels for the company are sitting at:
- -15.01 for the present operating margin
- 0.75 for the gross margin
The net margin for Compass Therapeutics Inc stands at -12.93. The total capital return value is set at -0.38. Equity return is now at value -36.07, with -33.22 for asset returns.
Based on Compass Therapeutics Inc (CMPX), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -6.99. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -29.59.
Currently, EBITDA for the company is -48.47 million with net debt to EBITDA at 0.56. When we switch over and look at the enterprise to sales, we see a ratio of 88.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.96.
Conclusion
In conclusion, Compass Therapeutics Inc (CMPX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
